Efficacy Comparison between New Tea Tree Oil Eyelid Cleanser and Commercial OcuSOFT Eyelid Cleanser in Treatment of Meibomian Gland Dysfunction: Randomized Controlled Paired-eye Trial

Office of Research Affairs0 个研究点目标入组 60 人开始时间: 2021年9月23日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Healthy adult aged 18-50 years who are currently working at the King Memorial Chulalongkorn Hospital
•1. non-invasive tear breakup time <10 seconds, 2. at least 1 clinical sign of meibomian gland dysfunction from each category 2.1 meibomian gland dropout, 2.2 altered meibomian gland expression, 2.3 changes in lid morphology

•1.Known hypersensitivity to known components in the new tea-tree oil eyelid cleanser, OcuSOFT eyelid cleanser
•2.Participants with previously diagnosed MGD who have had office lid cleansing treatment, intense pulse light therapy, or home lid hygiene within 1 month prior to the trial will excluded.
•3.Pregnant patients are excluded due to lack of embryotoxicity study.
•4.Participants with pre-existing diseases of eyelid, conjunctiva, cornea that risk being endangered by application of the cleansers or potentially compromise the study results, as following:
•-Acquired eyelid disorders, including chalazion, hordeolum, and eyelid neoplasm
•-Periocular malposition, including ectropion, entropion, symblepharon, trichiasis, distichiasis, eyelid retraction, and exposure keratopathy
•-Degenerative disorder of conjunctiva, including pinguecula, pterygium
•-Inflammatory disorders of cornea or systemic diseases involving ocular surface: Steven-Johnson syndrome, Sjogren syndrome, chemical damage, limbal stem cell deficiency, corneal dystrophies, neoplasm of conjunctiva and cornea, infectious keratoconjunctivitis, etc.
•5. Contact lens wear

发起方

Office of Research Affairs